Answers are grounded in this paper and cite their sources.
The excipient Cremophor EL in Taxol is responsible for metabolic dysregulation and increased triglycerides, highlighting the clinical impact of non-active pharmaceutical ingredients in cancer therapy.
Taxane-based reagents, such as Taxol, Taxotere, and Abraxane, are popular anti-cancer drugs that can differ in their clinical efficacy. This difference is generally attributed to their active pharmaceutical ingredients. Here, we report a serendipitous discovery that Taxol induces metabolic dysregulation and unfolded protein response. Surprisingly, these effects of Taxol are entirely dependent on its excipient, Cremophor EL (CrEL). We show that CrEL promotes aerobic glycolysis and in turn results in drastic upregulation of angiopoietin like 4 ( ANGPTL4 ), a major regulator of human blood lipid profile. Notably, premedication with dexamethasone further enhances the expression of ANGPTL4 . Consistently, we find that the amplitude and frequency of increase in triglycerides is more prominent in Taxol-treated patients with breast cancer. In addition, we find that CrEL activates the unfolded protein response pathway to trigger proinflammatory gene expression and caspase/gasdermin E-dependent pyroptosis. Finally, we discuss the implications of these results in anti-cancer therapies.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: